Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Loss of IRF-4–binding protein leads to the spontaneous development of systemic autoimmunity
Jessica C. Fanzo, … , Steven Greenberg, Alessandra B. Pernis
Jessica C. Fanzo, … , Steven Greenberg, Alessandra B. Pernis
Published March 1, 2006
Citation Information: J Clin Invest. 2006;116(3):703-714. https://doi.org/10.1172/JCI24096.
View: Text | PDF
Research Article Immunology

Loss of IRF-4–binding protein leads to the spontaneous development of systemic autoimmunity

  • Text
  • PDF
Abstract

IFN regulatory factor 4–binding (IRF-4–binding) protein (IBP) is a novel type of activator of Rho GTPases that is recruited to the immunological synapse upon TCR stimulation. Here we demonstrate that loss of IBP leads to the spontaneous development of a systemic autoimmune disorder characterized by the accumulation of effector/memory T cells and IgG+ B cells, profound hypergammaglobulinemia, and autoantibody production. Similar to human SLE, this syndrome primarily affects females. T cells from IBP-deficient mice are resistant to death in vitro as well as in vivo and exhibit selective defects in effector function. In the absence of IBP, T cells respond suboptimally to TCR engagement, as demonstrated by diminished ERK1/2 activation, decreased c-Fos induction, impaired immunological synapse formation, and defective actin polymerization. Transduction of IBP-deficient T cells with a WT IBP protein, but not with an IBP mutant lacking the Dbl-like domain required for Rho GTPase activation, rescues the cytoskeletal defects exhibited by these cells. Collectively, these findings indicate that IBP, a novel regulator of Rho GTPases, is required for optimal T cell effector function, lymphocyte homeostasis, and the prevention of systemic autoimmunity.

Authors

Jessica C. Fanzo, Wen Yang, So Young Jang, Sanjay Gupta, Qinzhong Chen, Ayesha Siddiq, Steven Greenberg, Alessandra B. Pernis

×

Figure 7

Defective ERK1/2 activation in IBPtrap/trap T cells.

Options: View larger image (or click on image) Download as PowerPoint
Defective ERK1/2 activation in IBPtrap/trap T cells.
(A) Lck and ZAP-70 ...
(A) Lck and ZAP-70 activation in IBPtrap/trap T cells was detected by Western blotting utilizing antibodies specific for Tyr 394 phosphorylated Lck (upper panel) and Tyr 319 phosphorylated ZAP-70 (middle panel). Reprobing with an antibody against total Lck is shown as a loading control (lower panel). (B) TCR-mediated calcium mobilization in IBP+/+ and IBPtrap/trap T cells. Lymph node cells were loaded with Fura-red and Fluo-4 and surface stained with APC-labeled anti-CD4 antibody. Cells were then precoated with 5 μg anti-CD3ε (2C11) antibody and cross-linked with goat anti-hamster Ig. Histogram data are presented as a median ratio of calcium mobilization gated on CD4+ cells as measured by FACS. The black line represents IBP+/+ T cells, and the gray line represents IBPtrap/trap T cells. Arrow indicates the addition of cross-linking antibody. (C) ERK activation in IBP+/+ and IBPtrap/trap T cells. Cells were stimulated with anti-CD3ε antibody for the indicated times or PMA (50 ng/ml) for 2 minutes as a control. Whole-cell lysates were prepared and active ERK1/2 detected by Western blotting using an anti–phosphorylated ERK antibody (upper panel). Total ERK1/2 levels are shown in the lower panel. (D) Induction of c-Fos in IBPtrap/trap T cells. Primed T cells from IBP+/+ and IBPtrap/trap mice were stimulated with anti-CD3ε antibody (5 μg/ml) and anti-CD28 antibody (5 μg/ml) for 0, 1, or 2 hours. Lysates were prepared and levels of c-Fos detected by Western blotting using an anti–c-Fos antibody (upper panel). Reprobing with a β-actin antibody is shown as a loading control (lower panel).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts